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Abstract
Background:  Outbreak reports suggest that community-acquired methicillin-resistant
Staphylococcus aureus (MRSA) infections can be life-threatening. We conducted a population based
cohort study to assess the magnitude of mortality associated with MRSA infections diagnosed in
the community.
Methods: We used the United Kingdom's General Practice Research Database (GPRD) to form
a cohort of all patients with MRSA diagnosed in the community from 2001 through 2004 and up to
ten patients without an MRSA diagnosis. The latter were frequency-matched with the MRSA
patients on age, GPRD practice and diagnosis date. All patients were older than 18 years, had no
hospitalization in the 2 years prior to cohort entry and medical history information of at least 2
years prior to cohort entry. The cohort was followed up for 1 year and all deaths and
hospitalizations were identified. Hazard ratios of all-cause mortality were estimated using the Cox
proportional hazards model adjusted for patient characteristics.
Results: The cohort included 1439 patients diagnosed with MRSA and 14,090 patients with no
MRSA diagnosis. Mean age at cohort entry was 70 years in both groups, while co-morbid conditions
were more prevalent in the patients with MRSA. Within 1 year, 21.8% of MRSA patients died as
compared with 5.0% of non-MRSA patients. The risk of death was increased in patients diagnosed
with MRSA in the community (adjusted hazard ratio 4.1; 95% confidence interval: 3.5–4.7).
Conclusion: MRSA infections diagnosed in the community are associated with significant mortality
in the year after diagnosis.
Background
Methicillin-resistant  Staphylococcus aureus (MRSA) is
increasingly implicated in potentially lethal hospital-
acquired infections [1,2]. Some of the MRSA strains that
are found in patients in the community have been
acquired during hospitalization or a visit to a hospital.
However, MRSA strains likely originating outside of hos-
pitals and different from those found in hospitals have
been identified [3-5]. People who are infected by MRSA in
the community have different risk factors than those
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infected in hospitals [1,2], particularly as common risk
factors in hospitals may be rare or absent in the commu-
nity.
While hospital-acquired MRSA infections can be fatal
[1,2], cases of severe and life-threatening MRSA infections
from the community have also been reported [6-8] and
these case reports suggest that the prognosis of commu-
nity-acquired MRSA infections may be poor [9]. However,
hospital-based studies do not capture patients from the
community whose infection does not require hospital
care, and thus such studies or case reports cannot evaluate
the impact of this infection on mortality. To date, no pop-
ulation-based study has evaluated the prognosis and mor-
tality of MRSA patients diagnosed in the community.
We thus conducted a large cohort study to assess mortality
associated with MRSA infections diagnosed in the com-
munity in comparison with a population-based sample of
patients free of this infection.
Methods
We used the General Practice Research Database (GPRD)
between 1 January 2001 and 31 December 2005 for this
study. The GPRD contains the diagnostic, testing and pre-
scribing records of approximately 3.2 million patients
from over 400 general practices in the United Kingdom
(UK) as recorded by their GPs. The GPRD is extensively
used for medical research [10,11] and has been used pre-
viously for prognostic work in cardiovascular disease [12],
as well as infectious disease research [13,14]. GPRD data
is routinely audited for quality [10] and is considered to
be of high validity for medical research.
Cohort definition and follow-up
We conducted a frequency-matched cohort study. The
cohort consisted of all patients with MRSA diagnosed
between 1 January 2001 and 31 December 2004, and a
population-based sample of patients without MRSA. We
defined MRSA to be the diagnosis 'Methicillin-resistant
Staphylococcus aureus positive' (READ code 4JP..00)
entered into the patient's medical record. The date of the
MRSA diagnosis was the MRSA patient's cohort entry date.
For each patient with MRSA, we randomly selected up to
10 patients free of MRSA that were registered in the GPRD
at their corresponding MRSA patient's cohort entry date
and that were matching on practice, cohort entry date and
age (± 2 years). We assigned to these MRSA-free patients
their corresponding MRSA patient's cohort entry date.
Patients of the cohort, both with and without MRSA, had
to be at least 18 years of age at their cohort entry date, had
been registered in the GPRD for at least 2 years prior to
their cohort entry date and had no hospitalizations
recorded in the GPRD in the 2 years before cohort entry
date. Frequency matching on cohort entry date is particu-
larly important to control for calendar time effects,
because the rate of MRSA diagnosis in the GPRD was not
constant over the time period of our study [13]. This time
variation in risk could have been a potential source of bias
in our estimates of effect [15]. By frequency matching on
practice we also ensured that patients with and without an
MRSA diagnosis came from the same geographic region of
the UK, thus indirectly controlling for factors such as
socio-economic status and geographical variations in dis-
ease frequency.
Follow-up was from day 1 to day 365 after cohort entry
date. Patients were censored if they transferred out of prac-
tice for a reason other than death or were free of the out-
come 365 days after cohort entry. Patients who died on
day 0 were excluded. It was possible for a patient without
MRSA to be diagnosed with MRSA during follow-up.
Outcome
The outcome, death, was defined as a transfer out of the
GPRD with the reason being 'Death' recorded in the
patient database of the GPRD. We used the date of the
transfer out as the date of death. As the GPRD is based on
GP records and deaths are a variable that practices in the
GPRD are audited on [10], death should be a well-
recorded variable in this database.
For a secondary outcome, to assess the level of morbidity
caused by MRSA infections diagnosed in the community,
we considered a composite outcome of either death or
hospitalization. For this outcome, the date of outcome
was either the date of hospitalization or the date of death;
whichever came first. The recording of reason for hospital-
ization is poor in the GPRD, but the hospital visit itself is
well recorded [10,11]. Therefore, we were not able to sep-
arate hospitalization by reason and used 'any cause' hos-
pitalization. The recording of hospitalization information
also made it impossible to assess whether or not patients
diagnosed with MRSA had serious infectious complica-
tions such as bacteraemia.
Covariates
In addition to age and sex, we defined a series of baseline
covariates that could have an impact on the prognosis of
individuals diagnosed with MRSA in the community. We
included the presence of cancer, heart disease, renal fail-
ure, autoimmune diseases and diabetes, all identified
using medical records in the GPRD in the 2 years prior to
cohort entry date. We also considered use of antibiotics
and oral prednisone in the year before cohort entry date.
Statistical analysis
We used the Kaplan-Meier method to estimate the cumu-
lative mortality in patients with and without MRSA over
the one-year follow-up. The Cox proportional hazardsBMC Medicine 2008, 6:2 http://www.biomedcentral.com/1741-7015/6/2
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model was used to estimate the hazard ratio of death asso-
ciated with MRSA infection, adjusting for covariates [16].
Proportionality of hazards was assessed using graphical
methods.
We conducted several sensitivity analyses. First, to deter-
mine the maximum possible effect of censoring on the
results, we used both worst-case and best-case imputation,
appropriate techniques because of the small number of
censored observations [17]. For worst-case imputation,
we assumed that all MRSA patients who were censored die
immediately and that all patients without MRSA lived
until the end of follow-up. For best-case imputation, we
assumed that all censored MRSA patients lived until the
end of follow-up and all censored MRSA-free patients
died immediately. Second, as an additional control for
overall health status, we considered past antibiotic use as
a marker of susceptibility to infection. Third, we deter-
mined the effect of MRSA diagnosis among patients with
none of the co-morbid conditions in our study to estimate
the effect of MRSA among healthy patients. We used SAS
version 9.1.3 in all analyses.
We obtained ethics approval for this study from the Scien-
tific and Ethical Advisory Group of the GPRD and the
McGill University Health Center Research Ethics Board.
Results
The cohort included 1439 patients diagnosed with MRSA
between 2001 and 2004, and 14,090 matching disease-
free patients from the GPRD. Over the one-year period
after cohort entry, 21.8% of patients diagnosed with
MRSA and 5.0% of those without the diagnosis died. The
Kaplan-Meier plot is shown in Figure 1. The loss to follow
up owing to transfer out of practice was comparable in the
patients with and without MRSA (4.2% and 3.0%, respec-
tively). Patients with MRSA diagnosis were more likely to
be male and to have co-morbid conditions predictive of
mortality as compared with patients without a diagnosis
of MRSA (Table 1).
Patients with a diagnosis of MRSA were more likely to die
than those without MRSA (unadjusted hazard ratio (HR),
4.85; 95% confidence interval (CI), 4.25–5.54; see Table
2). After adjustment for age, sex and the co-morbid condi-
tions listed in Table 1, the HR of death from any cause in
Kaplan-Meier plot of the cumulative probability of death up to 1 year in patients after diagnosis with MRSA by a GP and  patients without MRSA matched on diagnosis date, age and general practice Figure 1
Kaplan-Meier plot of the cumulative probability of death up to 1 year in patients after diagnosis with MRSA by 
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patients with MRSA compared with patients without
MRSA was 4.08 (95% CI: 3.54–4.69).
The cumulative incidence of the composite outcome of
death or hospitalization is depicted by the Kaplan-Meier
plots in Figure 2. Table 2 shows that the adjusted HR of
this outcome with MRSA infection is 3.31 (95% CI: 2.97–
3.69).
The sensitivity analysis for informative censoring pro-
duced an adjusted HR of 4.91 (95% CI: 4.30–5.61) for
worst-case imputation, and an adjusted HR of 2.69 (95%
CI: 2.36–3.07) for best-case imputation. Prior antibiotic
use had a small effect on mortality once we adjusted for
other factors with an adjusted HR of 1.30 (95% CI: 1.14–
1.49). Finally, among the subset of patients with no co-
morbidities, the effect of MRSA infection on mortality was
comparable to that obtained for all patients with an
adjusted HR of 4.86 (95% CI: 4.10–5.77).
Discussion
In this study, we demonstrated an increase in mortality
within a year of a diagnosis with an MRSA infection in the
community. This increased mortality cannot be com-
pletely explained by underlying co-morbid conditions as
we adjusted for the major risk factors of death. The four-
fold increase in mortality persisted across several sensitiv-
ity analyses. In addition, we found a risk increase of simi-
lar magnitude with the combined outcome of death and
hospitalization.
Table 2: All-cause mortality and hospitalization or all-cause mortality within a year in patients diagnosed with MRSA compared with 
matched patients free of MRSA from the GPRD (2001–2004) The hazard ratio is adjusted for all variables in Table 1. Death or 
hospitalization patients were followed until first event of either kind and only counted once.
Characteristic n Events Person-years of follow-up Rate of event per 
100 years
Crude HR Adjusted HR (95% CI)
Death
Patients with MRSA 1439 313 1224 25.6 4.85 4.08 (3.54–4.69)
Patients without MRSA 14,090 709 13510 5.2 1.00 1.00 (Reference)
Death or hospitalization
Patients with MRSA 1439 485 1106 43.9 3.93 3.31 (2.97–3.69)
Patients without MRSA 14090 1440 13106 10.2 1.00 1.00 (Reference)
Table 1: Baseline characteristics of patients diagnosed with MRSA (1439 subjects; mean ± SD age 70.3 ± 18.3 years) and a matched 
population sample free of MRSA (14,090 subjects; mean ± SD age 69.9 ± 18.2 years) from GPRD (2001–2004)
Characteristic Patients with MRSA Matched MRSA-free patients
n Percentage n Percentage
Male 604 42.0% 5988 42.5%
Female 835 58.0% 8102 57.5%
Co-morbidity in the 2 years prior to cohort entry
Diabetes 162 11.3% 877 6.2%
Cardiovascular disease 98 6.8% 467 3.3%
Stroke 74 5.1% 140 1.0%
Peripheral vascular disease 34 2.4% 72 0.5%
COPD 76 5.3% 364 2.6%
Renal failure 45 3.1% 138 1.0%
Cancer 27 1.9% 127 0.9%
Autoimmune disease 12 0.8% 66 0.5%
Drug exposure in the 1 year prior to cohort entry
Oral prednisone use 155 10.8% 858 6.1%
Antibiotics 1019 70.8% 5369 38.1%BMC Medicine 2008, 6:2 http://www.biomedcentral.com/1741-7015/6/2
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Patients with nosocomial MRSA bacteraemia [18,19] have
been reported as having as great as a ten-fold increased
risk of death [18]. However, these extremely severe infec-
tions are not representative of all nosocomial MRSA infec-
tions, and likely not representative of community-
acquired MRSA infections, many of which do not require
hospitalization [6]. As expected, our observed death rate is
much lower than in these studies.
In this study we observe an average of 360 MRSA infec-
tions diagnosed in the community per year among the
adult GPRD population during the study period. This is
about 13 cases per 100,000 adults in the GPRD popula-
tion, which is similar to the incidence found in other stud-
ies such as that by Fridkin et al [4]. This is especially true
if we assume that some MRSA infections are diagnosed in
hospital emergency rooms and thus not counted in our
study. Fridkin et al also found a significant proportion of
community-associated MRSA infections occurring in
patients above 65 years of age [4].
In this study we considered a large cohort of patients diag-
nosed with MRSA infections in the community and a large
group of matching disease-free patients all selected from a
database that is representative of the UK population [10].
The death rate among the disease-free patients is broadly
consistent for this age and sex distribution with that seen
in UK vital statistics [20]. Using the GPRD allows us to
study patients with all levels of disease severity encoun-
tered by GPs, including those not treated in hospitals and
thus not part of any hospital-based investigation. The
study design (frequency matched cohort study) ensured
that the distribution of key covariates (general practice,
age and calendar time) was balanced between patients
with and without MRSA at baseline. By matching on gen-
eral practice we indirectly matched on unmeasured factors
such as socio-economic status, area of residence and nurs-
ing home care, which are usually common to the patient
population of a given general practice. These demo-
graphic factors have been shown to be important in the
epidemiology of MRSA [21]. By matching for practice we
control for the potential confounding nature of these var-
iables.
There are nevertheless some limitations to our study. In
particular, we could not distinguish site or severity of indi-
Kaplan-Meier plot of the cumulative probability of hospitalization or death in patients up to 1 year after diagnosis with MRSA  by a GP and patients without MRSA, matched on diagnosis date, age and general practice Figure 2
Kaplan-Meier plot of the cumulative probability of hospitalization or death in patients up to 1 year after diag-
nosis with MRSA by a GP and patients without MRSA, matched on diagnosis date, age and general practice. 







0 50 100 150 200 250 300 350
















































0 50 100 150 200 250 300 350









































Patients without MRSABMC Medicine 2008, 6:2 http://www.biomedcentral.com/1741-7015/6/2
Page 6 of 8
(page number not for citation purposes)
vidual MRSA infections. As we could not examine antibi-
otics given in hospital, it was not feasible to use post-
diagnosis treatment either to separate infection site or
infection source as different therapy is recommended for
community-acquired MRSA [22]. However, our observed
mortality of MRSA infections diagnosed by general practi-
tioners in the community rules out that these are the
extremely severe infections seen in hospitals [18]. On the
other hand, these results imply that individuals with
MRSA diagnoses in the GPRD are not mostly asympto-
matic carriers but include clinically significant infections:
a conclusion supported by other work in the GPRD on
MRSA infections [13]. Moreover, we strongly believe that
currently, general practitioners in the UK do not routinely
screen and thus diagnose MRSA in asymptomatic individ-
uals in the community.
We could not exclude the possibility that some MRSA
infections were acquired in hospitals and not in the com-
munity, because we had no information on potential
transmission from visits to or work in hospitals. We could
not look at the spread of MRSA from close contacts [23]
or clusters in workplaces or schools [24]. Therefore, we
describe here the prognosis of MRSA infections detected
by general practitioners, but we cannot demonstrate that
these infections arose independently in the community.
However, the high mortality rate underlines the impor-
tance of their control. To contribute to achieving this, we
recently proposed the appropriate use of antibiotics [13].
The increased mortality observed for MRSA infections
may be a result of a health state that predisposes to MRSA
infections or residual confounding by this health state.
Frailty and residing in a nursing home are examples of
potential confounders that we were unable to adjust for in
this study. If the mortality associated with MRSA is a man-
ifestation of underlying susceptibility to infections, then
past antibiotic use could serve as an estimate of the degree
of bias in our study. Past antibiotic use should not be
associated with distant outcomes but will show patients
who have a history of infections. While we found a small
increase in mortality predicted by antibiotic prescriptions
given in the year prior to cohort entry, it was much too
small to be a major confounder of the observed increase
in mortality. Therefore, some degree of susceptibility to
infection may explain a small part of the increased death
rate. However, because of the small size of this effect we
can infer that the risk of death in this study is not princi-
pally a marker of an underlying susceptibility to infec-
tions.
We did not report on the effect of antibiotic therapy on
mortality after MRSA diagnosis for three reasons. One, the
GPRD does not report drug exposures during hospitaliza-
tion. This would result in the most severe cases of MRSA
infection being misclassified as unexposed. This could
lead to a falsely protective effect of antibiotic use if it was
only recorded among the healthiest patients. Two, the use
of antibiotics would be a dynamic treatment regime and
more advanced statistical methods would be required to
obtain a valid estimate [25]. Three, the GPRD recording
system does not allow us to determine whether an antibi-
otic prescription is being given for the original infection or
for a second infection that developed independently.
While previous work in this database has shown differ-
ences between classes of antibiotics and the development
of MRSA diagnosed in the community [13], we did not see
any strong link between antibiotic class and prognosis.
Therefore, we considered antibiotics only as a single drug
class for this analysis as the principal reason for including
antibiotics as a covariate was to control for possible differ-
ences in susceptibility to infections between patients with
and without MRSA.
The broad use of sensitivity analysis [26,27] is a key
strength of our study. The results of these analyses indicate
that the increase in mortality after a diagnosis of MRSA is
robust to changes in assumptions. The use of the READ
code 4JP..00 for MRSA infection has been discussed previ-
ously [13] and patients with this code were more similar
in characteristics to post-operative MRSA wound infec-
tions than to carriers. The very high mortality rate seen in
patients with MRSA in the present study, independent of
baseline health status, is also highly suggestive of infec-
tions rather than carrier status. However, carrier status
may be associated with lower mortality and hospitaliza-
tion rate in comparison to clinically relevant infections.
Thus, including this code may have led to an underestima-
tion of the impact of a diagnosis of MRSA in the commu-
nity on hospitalization and mortality.
The largest remaining source of possible bias in this study
is the possibility of unmeasured confounding or, more
likely, residual confounding. While non-parametric
approaches could be used to reduce residual confounding
in this study, they are unlikely to explain effects of the size
that we observe [28]. It is not likely that such large effects
could be explained by anything other than many
extremely strong confounders [29] based on estimates of
the effect of confounding. We also avoided introducing
bias from either the misallocation of person time [30] or
from adjusting for variables potentially in the causal path-
way between MRSA infection and mortality [31] by defin-
ing confounders using only the baseline characteristics of
the subjects. Adjusting for factors (such as secondary
infections) that arise after the diagnosis of MRSA infection
could lead to overadjustment [32] and could bias the esti-
mates towards the null.BMC Medicine 2008, 6:2 http://www.biomedcentral.com/1741-7015/6/2
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Conclusion
In conclusion, our study suggests that MRSA can be a
potentially serious infection in the community leading to
increased mortality. Further research will allow a better
understanding of MRSA diagnosed in the community and
the prognosis of patients with this diagnosis. This is essen-
tial for effective prevention of MRSA arisen from the com-
munity, which will not only reduce hospital admissions
with infections, spread into and within hospitals, and
transmission in the community, but also likely will pre-
vent deaths in the community.
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